BREAKING
Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 17 minutes ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 2 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 4 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 5 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 6 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 7 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 9 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 9 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 10 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 10 hours ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 17 minutes ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 2 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 4 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 5 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 6 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 7 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 9 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 9 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 10 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 10 hours ago
ADVERTISEMENT

Crawford & Company (CRD-A) Earnings: 3Q22 Key Numbers

Crawford & Company (NYSE: CRD-A) reported revenues before reimbursements of $294.9 million for the third quarter of 2022, up 2% year-over-year. Net loss attributable to shareholders was $15.1 million, or $0.31 per share, compared to net income of $11.2 million, or $0.20 per share, last year. Adjusted EPS was $0.16. Consolidated cash and cash equivalents […]

November 8, 2022 1 min read

Crawford & Company (NYSE: CRD-A) reported revenues before reimbursements of $294.9 million for the third quarter of 2022, up 2% year-over-year.

Net loss attributable to shareholders was $15.1 million, or $0.31 per share, compared to net income of $11.2 million, or $0.20 per share, last year. Adjusted EPS was $0.16.

Consolidated cash and cash equivalents as of September 30, 2022, were $33.1 million.

ADVERTISEMENT